Phase I clinical trial combining imatinib mesylate and IL-2

The Critical Role of IL-15 in the Antitumor Effects Mediated by the Combination Therapy Imatinib and IL-2

(2014) G. Mignot et al.   JOURNAL OF IMMUNOLOGY

Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL- Tumors

(2014) N. Larmonier et al.   JOURNAL OF IMMUNOLOGY

Trans-Presentation of IL-15 Dictates IFN-Producing Killer Dendritic Cells Effector Functions

(2014) E. Ullrich et al.   JOURNAL OF IMMUNOLOGY

Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV

(2012) Yves Lévy et al.   AIDS

Redefining interferon-producing killer dendritic cells as a novel intermediate in NK-cell differentiation

(2012) F. Guimont-Desrochers et al.   BLOOD

Exploiting antitumor immunity to overcome relapse and improve remission duration

(2011) Lei L. Chen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A distinct subset of human NK cells expressing HLA-DR expand in response to IL-2 and can aid immune responses to BCG

(2011) J. Henry Evans et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

(2011) Vinod P Balachandran et al.   NATURE MEDICINE

Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis

(2011) David Saadoun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

(2011) John Koreth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunomodulatory effects of cyclophosphamide and implementations for vaccine design

(2011) Antonella Sistigu et al.   Seminars in Immunopathology

Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients

(2010) S. Viaud et al.   CANCER RESEARCH

Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis

(2010) G. Schiavoni et al.   CANCER RESEARCH

Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients

(2010)   JOURNAL OF CLINICAL ONCOLOGY

Natural Killer Cell IFN-  Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients

(2009) C. Menard et al.   CANCER RESEARCH

Cyclophosphamide and cancer: golden anniversary

(2009) Ashkan Emadi et al.   Nature Reviews Clinical Oncology

Cyclophosphamide Chemotherapy Sensitizes Tumor Cells to TRAIL-Dependent CD8 T Cell-Mediated Immune Attack Resulting in Suppression of Tumor Growth

(2009) Robbert G. van der Most et al.   PLoS One

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY